57445 HCC were registered 31743 HCC with complete data 10114 underwent surgical resection 9577 underwent local ablation therapies 9283 underwent TACE 1150.

Slides:



Advertisements
Similar presentations
Intermediate stage HCC management
Advertisements

Staging Strategy and Treatment for Patients With HCC
Radiotherapeutic Option in Management of Hepatocellular Carcinoma
High Intensity Focused Ultrasound (HIFU) for Liver Tumour Dr Dai Wing Chiu Queen Mary Hospital.
High-Intensity Focused Ultrasound for Hepatocellular Carcinoma Joint Hospital Surgical Grand Round Queen Mary Hospital 19/10/2013.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Interventional Oncology Michael Kotton MD October 27, 2012.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Journal Meeting 時間 : AM 07:30 日期 : 06/29/2007 地點 : 胸腔外科辦公室 報告人 : R2 許博順.
Hepatocellular carcinoma Diagnosis, Treatment, Prognosis + Quiz Vinko Bubic Mentor: A. Žmegač Horvat.
Management of Colorectal Liver Metastasis
Hepatocellular Carcinoma Aaron Wagner MS IV November 12, 2008.
Hepatocellular Carcinoma Detection and Treatment
Liver Cancer Management with Y90 Glass Microspheres – TheraSphere Experience and Challenges in HCC Thomas Lauenstein, MD Department of Diagnostic and.
MANAGEMENT OF RUPTURED HEPATOCELLULAR CARCINOMA Joint Hospital Surgical Grand Round 19 th July 2014 Dr. SC Tam United Christian Hospital.
A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.
The role of adjuvant TACE after curative liver resection for HCC
HCC Guidelines and recommendation Typical feature (wash in/wash out) New mass/nodule NoYes Alternative imaging technique Atypical featureTypical.
4 YEARS SURVIVAL OF 100 HCC PATIENTS TREATED WITH DC BEAD: A RETROSPECTIVE ANALYSIS Marta Burrel Vascular Interventional Unit Barcelona Clinic Liver Cancer.
ACRIN 6673 Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients: A Multi-Center Study.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Improved Survival of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients with Undetectable HIV RNA Oral Poster Presentation Tuesday, 20 July 2010 Emma.
HCC Guidelines
Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”
HCC Guidelines and recommendation Diagnostic algorithm and recall policy.*One imaging technique only recommended in centers of excellence with high-end.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
CLINICAL OUTCOME OF 251 PATIENTS WITH EXTRAHEPATIC METASTASIS AT INITIAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE.
Treatment Strategy for Recurrent Hepatocellular Carcinoma: Salvage Transplantation, Repeated Resection, or Radiofrequency Ablation? Albert C. Y. Chan,
Management of Hepatocellular carcinoma
K Nouso, K Miyahara, D Uchida, K Kuwaki, N Izumi, M Omata, T Ichida, M Kudo, Y Ku, N Kokudo, M Sakamoto, O Nakashima, T Takayama, O Matsui, Y Matsuyama,
TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Liver Cancer.
Figure 2 Forest plot of 3 studies evaluating the short-term patient-reported measures of activity limitations and participation restrictions (PRMALP) improvement.
Hepatocellular Carcinoma: Diagnosis and Management
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Volume 61, Issue 1, Pages (July 2014)
Chemotherapy for Liver Metastasis Originating from Colorectal Cancer with Portal Vein Tumor Thrombosis: A Case Report Case Rep Oncol 2013;6:
Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma  Mary A. Maluccio, MD, MPH, Anne M.
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Fig. 3. Comparative RFS in response to combination of RFA and TACE vs
Barcelona Clinic Liver Cancer (BCLC) staging classification and treatment schedule. Patients with very early hepatocellular carcinoma (HCC) (stage 0) are.
Hepatocellular carcinoma
Successful TACE for HCC
What does this protein make up or do?
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
The 44th Congress of the Korean Association of HBP Surgery
HEPATOCELLULAR CARCINOMA (HCC) at
Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database  Daniel J. Boffa,
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Hepatocellular Carcinoma: Overcoming Challenges in Disease Management
高雄長庚 大腸直腸外科 吳昆霖 盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全
Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E
A B Yeom Supplementary Fig.2
Epidemiology & First option of treatment
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases  Tao.
A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer  Christopher.
KAHBPS , Gyeongju, Korea Long-term outcome after resection of huge hepatocellular carcinoma ≥10 cm: Single-institution experience with 471 patients:
Targeted Therapies for Hepatocellular Carcinoma
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.
Bile duct invasion itself can be the prognosis factor in early HCC
Josep M. Llovet, Robert Montal, Augusto Villanueva 
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.
Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.
Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.
Surgical resection of metachronous liver metastases
Partial hepatectomy vs
Presentation transcript:

57445 HCC were registered HCC with complete data underwent surgical resection 9577 underwent local ablation therapies 9283 underwent TACE 1150 underwent chemotherapy 827 received other treatments such as radiation therapy 476 underwent continuous arterial infusion of 5-FU and CDDP* 674 underwent other chemotherapy were excluded due to insufficient data 1466 received no active therapy* Supplementary Figure 1. Flow of participants into the study. Survival of two groups with asterisk were compared. HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; 5-FU, 5- fluorouracil; CDDP, cisplatin.

SubgroupHR95% CI HBsAg-positive –0.62 HBsAg-negative –0.57 More than 3 tumors –0.49 Fewer than 3 tumors –0.69 Tumor size >3cm –0.54 Tumor size ≤3cm –0.86 Distant metastasis –0.54 No distant metastasis –0.70 VP 0/1/ –0.67 VP 3/ –0.49 Alpha-fetoprotein >400 ng/mL –0.54 Alpha-fetoprotein ≤400 ng/mL – Supplementary Figure 2. Forest plot for the risk of hepatic arterial infusion of 5-fluorouracil and cisplatin (HAIC). Subgroup analysis showed a benefit of HAIC compared with no active therapy regardless of the values of prognostic factors. HR, hazard ratio; CI, confidence interval.

Survival Rate Months after diagnosis Patients at risk HAIC No therapy HAIC No therapy Supplemantary Figure 3. Survival of propensity score-matched patients with Child-Pugh A/B disease and more than three tumors. Patients who underwent hepatic arterial infusion of 5- fluorouracil and cisplatin (HAIC) or no active therapy (no therapy) were compared. Median survival times were 13.9 months (HAIC) and 3.7 months (no therapy) (P<.0001).

Months after diagnosis Survival Rate Patients at risk HAIC No therapy HAIC No therapy - Supplementary Figure 4. Survival of propensity score-matched patients with Child-Pugh A/B disease and portal vein tumor thrombus. Patients who underwent hepatic arterial infusion of 5- fluorouracil and cisplatin (HAIC) or no active therapy (no therapy) were compared. Median survival times were 7.9 months (HAIC) and 3.1 months (no therapy) (P<.0001).